Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Twin City Bio is a contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, with a particular focus on regenerative medicine and advanced cellular therapies. Acquired by ProKidney in 2019, the company serves as the primary manufacturing affiliate for the Renal Advanced Cell Therapy (ReACT) program, an autologous cell therapy designed to treat chronic kidney disease. Twin City Bio provides comprehensive services including process development, cell line and medium optimization, gene therapy manufacturing, and quality control testing. The company's expertise in progenitor cell biology and large-scale autologous cell expansion supports the clinical advancement of transformational medical technologies toward commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Twin Cities Business.